151 related articles for article (PubMed ID: 9733145)
1. Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH).
Monti S; Di Silverio F; Toscano V; Martini C; Lanzara S; Varasano PA; Sciarra F
J Androl; 1998; 19(4):428-33. PubMed ID: 9733145
[TBL] [Abstract][Full Text] [Related]
2. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
Monti S; Sciarra F; Adamo MV; Toscano V; Trotta MC; Martini C; Lanzara S; Silverio FD
J Androl; 1997; 18(5):488-94. PubMed ID: 9349746
[TBL] [Abstract][Full Text] [Related]
3. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
Di Silverio F; Monti S; Sciarra A; Varasano PA; Martini C; Lanzara S; D'Eramo G; Di Nicola S; Toscano V
Prostate; 1998 Oct; 37(2):77-83. PubMed ID: 9759701
[TBL] [Abstract][Full Text] [Related]
5. Regional distribution of epidermal growth factor, testosterone and dihydrotestosterone in benign prostatic hyperplasia tissue.
Sciarra F; Monti S; Adamo MV; Palma E; Toscano V; d'Eramo G; di Silverio F
Urol Res; 1995; 23(6):387-90. PubMed ID: 8788277
[TBL] [Abstract][Full Text] [Related]
6. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
Krieg M; Bartsch W; Thomsen M; Voigt KD
J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
[TBL] [Abstract][Full Text] [Related]
7. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells.
Vignozzi L; Cellai I; Santi R; Lombardelli L; Morelli A; Comeglio P; Filippi S; Logiodice F; Carini M; Nesi G; Gacci M; Piccinni MP; Adorini L; Maggi M
J Endocrinol; 2012 Jul; 214(1):31-43. PubMed ID: 22562653
[TBL] [Abstract][Full Text] [Related]
8. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Vis AN; van Moorselaar RJ; Bui HN; Blankenstein MA; Meuleman EJ; Heijboer AC
BJU Int; 2012 Jan; 109(2):176-82. PubMed ID: 21992222
[TBL] [Abstract][Full Text] [Related]
9. [Measurement of T and DHT contents in normal and diseased human prostate tissues].
Zhang Y; Ye L; Ding Q; Fang Z; Yao M; Shi D
Zhonghua Wai Ke Za Zhi; 2000 Jul; 38(7):545-7. PubMed ID: 11832106
[TBL] [Abstract][Full Text] [Related]
10. Effects of two different medical treatments on dihydrotestosterone content and androgen receptors in human benign prostatic hyperplasia.
Petrangeli E; Sciarra F; Di Silverio F; Toscano V; Lubrano C; Conti C; Concolino G
J Steroid Biochem; 1988; 30(1-6):395-9. PubMed ID: 2455099
[TBL] [Abstract][Full Text] [Related]
11. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
[TBL] [Abstract][Full Text] [Related]
12. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
[TBL] [Abstract][Full Text] [Related]
13. Concentration of dihydrotestosterone and 3 alpha-androstanediol in naturally occurring and androgen-induced prostatic hyperplasia in the dog.
Moore RJ; Gazak JM; Quebbeman JF; Wilson JD
J Clin Invest; 1979 Oct; 64(4):1003-10. PubMed ID: 90055
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-I and -II in human benign prostatic hyperplasia: relationship with binding proteins 2 and 3 and androgens.
Monti S; Di Silverio F; Lanzara S; Varasano P; Martini C; Tosti-Croce C; Sciarra F
Steroids; 1998; 63(5-6):362-6. PubMed ID: 9618803
[TBL] [Abstract][Full Text] [Related]
15. Clinical study on estramustine binding protein (EMBP) in human prostate.
Shiina H; Igawa M; Ishibe T
Prostate; 1996 Sep; 29(3):169-76. PubMed ID: 8827085
[TBL] [Abstract][Full Text] [Related]
16. Supranormal nuclear content of 5 alpha-dihydrotestosterone in benign hyperplastic prostate of humans.
Meikle AW; Collier ES; Middleton RG; Fang SM
J Clin Endocrinol Metab; 1980 Oct; 51(4):945-7. PubMed ID: 6158523
[TBL] [Abstract][Full Text] [Related]
17. Estradiol/androgen receptors during aging: microsomal distribution in human benign prostatic hypertrophy.
Salazar EL; Calzada L; Escontria M
Arch Androl; 2005; 51(1):49-53. PubMed ID: 15764417
[TBL] [Abstract][Full Text] [Related]
18. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
19. Conversion of 3H-testosterone to dihydrotestosterone in human hypertrophic prostatic tissue.
Baranowska B; Zgliczyński S
Nuklearmedizin; 1979; 18(6):297-9. PubMed ID: 94161
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor isoforms in human and rat prostate.
Xia SJ; Hao GY; Tang XD
Asian J Androl; 2000 Dec; 2(4):307-10. PubMed ID: 11202423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
